It is Pharma Time: Why Merck and Lilly Stock Are Buys, but not Pfizer.
My 2023 biotech outlook calls for ongoing momentum in title variations. I just will need to ...
Read moreMy 2023 biotech outlook calls for ongoing momentum in title variations. I just will need to ...
Read morePfizer is preparing to pull again on early-phase research into treatments for exceptional illnesses, which include ...
Read moreAs buyers confront another uncertain year for public equities, huge-cap health care stocks remain an beautiful ...
Read moreJournal Studies: LeadershipHow the Administration Prime 250 Rankings Are PickedDecember 11, 2022 at 2:01 PM ETThe ...
Read moreJournal Stories: ManagementAmong the Very best-Managed Businesses of 2022, Some Warning SignsBy Chris KornelisDecember 11, 2022 ...
Read moreHorizon Therapeutics Fields Takeover Fascination From Pharma Giants
Read moreBye-Bye, Bear Sector? The Worst Could Be In excess of for Shares.
Read moreJoe Rosenberg’s connection with Barron’s goes back again to 1963, when he wrote a bullish posting ...
Read morePfizer Inc.'s PFE, -1.86% COVID-19 antiviral Paxlovid brought in $7.5 billion in revenue in the 3rd ...
Read morePfizer is set to report its earnings on Tuesday, a week and a 50 % soon ...
Read more